Sergio Traversa - 16 May 2025 Form 4 Insider Report for RELMADA THERAPEUTICS, INC. (RLMD)

Role
Chief Executive Officer, Director
Signature
/s/ Sergio Traversa
Issuer symbol
RLMD
Transactions as of
16 May 2025
Net transactions value
+$174,713
Form type
4
Filing time
20 May 2025, 18:01:43 UTC
Previous filing
11 Sep 2024
Next filing
30 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
TRAVERSA SERGIO Chief Executive Officer, Director C/O RELMADA THERAPEUTICS, INC., 2222 PONCE DE LEON BLVD, 3RD FLOOR, CORAL GABLES /s/ Sergio Traversa 20 May 2025 0001565832

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RLMD Common Stock Purchase $77,472 +172,314 +45% $0.4496 556,338 16 May 2025 Direct F1, F2
transaction RLMD Common Stock Purchase $14,994 +30,000 +5.4% $0.4998 586,338 19 May 2025 Direct F1, F3
transaction RLMD Common Stock Purchase $82,246 +147,686 +25% $0.5569 734,024 20 May 2025 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.
F2 Purchase prices range from $0.4485 to $0.4564 per share, inclusive.
F3 Purchase prices range from $0.4998 to $0.50 per share, inclusive.
F4 Purchase prices range from $0.53 to $0.59 per share, inclusive.